文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

接受丙泊酚的COVID-19危重患者高甘油三酯血症评估

Evaluation of Hypertriglyceridemia in Critically Ill Patients With Coronavirus Disease 2019 Receiving Propofol.
PubMed 文献 · Crit Care Explor · 2021-01-11
一句话结论接受丙泊酚的COVID-19 ICU患者高甘油三酯血症发生率56.6%,中位发生时间46小时,建议丙泊酚使用超过24小时者频繁监测血清甘油三酯。

这项单中心回顾性观察分析纳入2020年3月1日至4月20日在Brigham and Women's Hospital ICU接受丙泊酚的106例COVID-19患者。主要结局为高甘油三酯血症(血清甘油三酯>400 mg/dL)的发生率及危险因素,次要结局包括急性胰腺炎和丙泊酚使用指标。60例(56.6%)发生高甘油三酯血症,中位发生时间46小时;发生者中35例(58.5%)继续使用丙泊酚,中位持续105小时。丙泊酚累积剂量和持续时间均非高甘油三酯血症的危险因素。

要点

  • 106例接受丙泊酚的COVID-19 ICU患者中60例(56.6%)发生高甘油三酯血症(血清甘油三酯>400 mg/dL),中位发生时间46小时。
  • 发生高甘油三酯血症者中35例(58.5%)继续使用丙泊酚,中位持续105小时,原文指出许多患者在降低剂量后可继续使用丙泊酚。
  • 丙泊酚累积剂量和持续时间均未被识别为高甘油三酯血症的危险因素。
  • 5例临床怀疑急性胰腺炎,仅1例影像学确诊。
  • 发生高甘油三酯血症的患者炎症标志物水平升高。

适用人群与场景

  • 2020年3月1日至4月20日在Brigham and Women's Hospital(波士顿三级学术医疗中心)ICU接受丙泊酚的COVID-19患者,共106例。

诊断标准与关键阈值

  • 高甘油三酯血症定义为血清甘油三酯水平>400 mg/dL。
  • 建议对需要丙泊酚超过24小时的患者频繁监测血清甘油三酯水平。

处置流程与药物剂量

  • 原文未提及具体的丙泊酚剂量调整方案或高甘油三酯血症处理流程;仅报告发生高甘油三酯血症者中35例(58.5%)在降低剂量后继续使用丙泊酚,中位持续105小时。

红旗征与不能漏的情况

  • 5例患者临床怀疑急性胰腺炎,其中1例经影像学确诊。

研究设计与关键结果

  • 单中心、回顾性、观察性分析,纳入106例接受丙泊酚的COVID-19 ICU患者。
  • 60例(56.6%)发生高甘油三酯血症,中位发生时间46小时。
  • 发生高甘油三酯血症者中35例(58.5%)继续使用丙泊酚,中位持续105小时。
  • 丙泊酚剂量或持续时间在高甘油三酯血症组与未发生组之间无差异。
  • 5例临床怀疑急性胰腺炎,1例影像学确诊。
  • 发生高甘油三酯血症的患者炎症标志物水平升高。

证据类型、等级与局限

  • 单中心、回顾性、观察性分析,样本量106例;原文未提及证据等级或推荐强度。
  • 局限:单中心、回顾性设计、样本量小、无对照组干预。

对床旁实践的改变

  • 对需要丙泊酚超过24小时的COVID-19 ICU患者应频繁监测血清甘油三酯水平。
  • 丙泊酚累积剂量和持续时间不是高甘油三酯血症的危险因素,不应仅依据剂量或持续时间决定是否监测。
  • 发生高甘油三酯血症后,降低丙泊酚剂量后许多患者可继续使用丙泊酚,但原文未给出具体剂量调整方案。
  • 需警惕急性胰腺炎,原文中5例临床怀疑、1例影像学确诊。

指南或共识出处

  • 原文未提及指南或共识出处;研究发表于Crit Care Explor。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To report the prevalence of, and evaluate risk factors for, the development of hypertriglyceridemia (defined as a serum triglyceride level of > 400 mg/dL) in patients with coronavirus disease 2019 who received propofol.

DESIGN: Single-center, retrospective, observational analysis.

SETTING: Brigham and Women's Hospital, a tertiary academic medical center in Boston, MA.

PATIENTS: All ICU patients who with coronavirus disease 19 who received propofol between March 1, 2020, and April 20, 2020.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The major outcome of this analysis was to report the prevalence of, and risk factors for, the development of hypertriglyceridemia in patients with coronavirus disease 19 who received propofol. Minor outcomes included the development of acute pancreatitis and description of propofol metrics. Of the 106 patients that were included, 60 (56.6%) developed hypertriglyceridemia, with a median time to development of 46 hours. A total of five patients had clinical suspicion of acute pancreatitis, with one patient having confirmatory imaging. There was no difference in the dose or duration of propofol in patients who developed hypertriglyceridemia compared with those who did not. In the patients who developed hypertriglyceridemia, 35 patients (58.5%) continued receiving propofol for a median duration of 105 hours. Patients who developed hypertriglyceridemia had elevated levels of inflammatory markers.

CONCLUSIONS: Hypertriglyceridemia was commonly observed in critically ill patients with coronavirus disease 2019 who received propofol. Neither the cumulative dose nor duration of propofol were identified as a risk factor for the development of hypertriglyceridemia. Due to the incidence of hypertriglyceridemia in this patient population, monitoring of serum triglyceride levels should be done frequently in patients who require more than 24 hours of propofol. Many patients who developed hypertriglyceridemia were able to continue propofol in our analysis after reducing the dose.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Kovacevic MP, Dube KM, Lupi KE, et al. Evaluation of Hypertriglyceridemia in Critically Ill Patients With Coronavirus Disease 2019 Receiving Propofol. Crit Care Explor. 2021. PMID: 33490957. doi:10.1097/CCE.0000000000000330

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。